TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25509255
Drug: Shuxuening Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuxuening Injection (SI) 15 mL, twice daily for 14 days
Study: 22574591
Drug: Shuxuening Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuxuening Injection (SI)
Study: 7105431
Drug: Intravenous labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous labetalol (100 mg)
Study: 17302079
Drug: Intranasal meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal meperidine
Study: 25972155
Drug: Intranasal butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal butorphanol
Study: 15034108
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy with conjugated estrogens and medroxyprogesterone acetate
Study: 19210012
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Adherence and Depression (CBT-AD)
Study: 28161016
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (cold wall oxygen 100% via infant nasal cannulae at low flow to a maximum of 2 L/min)
Study: 26525809
Drug: Basic (standard)
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic (standard) treatment (B vitamins, lipoic acid)
Study: 25006405
Drug: Oral tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tadalafil (40 mg daily for 12 months)
Study: 16510377
Drug: Fluvastatin XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin XL 80 mg once daily
Study: 8314497
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose interferon alfa‐2b (10 million units three times weekly subcutaneously for 16 weeks) after six weeks of prednisone (followed by a two week drug-free period)
Study: 8314497
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose interferon alfa‐2b
Study: 2967932
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (5 micrograms)
Study: 2967932
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (5 micrograms) plus immunoglobulin (0.25 ml/kg)
Study: 29941402
Drug: Experimental moisturizing
Normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental moisturizing mouthwash (1 to 2 doses/day for 8 days)
Study: 15576394
Drug: COC and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: COC and metformin (1500 mg/day) for 6 months
Study: 7623902
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and glyburide (protocol 2)
Study: 7623902
Drug: Metformin (protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (protocol 1)
Study: 7261663
Drug: Topical thrombin
Normalized name: thrombin Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical thrombin
Study: 31415033
Drug: everolimus (mTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: everolimus (mTOR inhibitor)
Study: 23869233
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg kg(-1) day(-1))
Study: 16461311
Drug: Intermittent subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent subcutaneous low-dose IL-2
Study: 10365634
Drug: Citalopram (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (40 mg/d)
Study: 10365634
Drug: Clomipramine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (75 mg/d)
Study: 8963484
Drug: Oral dexniguldipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexniguldipine (750 mg/d, 1,500 mg/d, 2,250 mg/d) for 3 consecutive weeks
Study: 8963484
Drug: Intravenous dexniguldipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexniguldipine (2 mg/kg body weight)
Study: 8963484
Drug: Oral dexniguldipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexniguldipine
Study: 1882877
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy review alone (control group)
Study: 10323113
Drug: Methadone 10
Normalized name: normethadone 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone 10 mg
Study: 26659582
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (500 μg bid)
Study: 21697535
Drug: Conjugated linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated linoleic acid (CLA) 4.5 g/d
Study: 19128672
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg lansoprazole daily
Study: 10869264
Drug: Sitaxsentan (1.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitaxsentan (1.5, 3.0, or 6.0 mg/kg)
Study: 1413921
Drug: ACTH-related hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTH-related hormones
Study: 1413921
Drug: Corticotropin releasing-hormone
Normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotropin releasing-hormone
Study: 6368241
Drug: Metoclopramide (MCP)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (MCP) given i.v. in 4 doses of 1 mg/kg over a period of 4 1/2 hr
Study: 6368241
Drug: Dexamethazone (DXM)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethazone (DXM) administered i.m. in 4 doses of 8 mg over 24 hr and another 10 mg i.v. just prior to CDDP administration
Study: 30514352
Drug: Weekly one-hour
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly one-hour multi-component training session within a WHPP over a one-year period
Study: 23996739
Drug: Domperidone syrup
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone syrup 0.15 mL/kg three times a day for 3 months along with PEG solution 0.6 g/kg/day two times a day for 6 months
Study: 31542082
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg per week starting from the first day after menstruation
Study: 24600231
Drug: Pantethine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantethine (600 mg/day from weeks 1 to 8 and 900 mg/day from weeks 9 to 16)
Study: 17697903
Drug: Extended-release metformin
Normalized name: metformin Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release metformin (MER) plus sulfonylurea (glyburide)
Study: 9506323
Drug: Withdrawal from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal from digoxin therapy
Study: 29326331
Drug: Low-flow oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flow oxygen therapy (LFO2) for 2 months
Study: 27190087
Drug: Linagliptin plus
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linagliptin plus pioglitazone 15 mg
Study: 22409999
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin administration to keep blood glucose between 6 and 8 mmol/l during surgery (n = 9)
Study: 20959577
Drug: DHA-rich fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich fish oil capsules (800 mg/d of DHA)
Study: 20959577
Drug: Vegetable oil
Normalized name: Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetable oil capsules without DHA (control)
Study: 9087976
Drug: Selegiline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline and alpha-tocopherol treatment
Study: 8403805
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose loading
Study: 3288525
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose of clavulanate‐potentiated amoxycillin (1200 mg) 2 hours before surgery
Study: 3288525
Drug: Intravenous cefotaxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cefotaxime (2 g each) in three doses during surgery, and 6 and 12 hours after surgery
Study: 28751300
Drug: 10-week Internet-based
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-week Internet-based guided self-help program with weekly therapist support via encrypted email
Study: 23052541
Drug: 0.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg of 20% mannitol 150 min after the initiation of pneumoperitoneum
Study: 19029316
Drug: Posaconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole (400 mg twice daily)
Study: 25179689
Drug: APF530 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: APF530 500 mg
Study: 16968847
Drug: Wait-and-see prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait-and-see prescription (WASP)
Study: 18753749
Drug: Restorations with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restorations with leakage (L+)
Study: 12492754
Drug: Motivational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motivational intervention (treatment as usual plus a one-session brief motivational intervention)
Study: 8940324
Drug: Alcohol ingestion
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol ingestion (0.7 g/kg) in control women not on ERT
Study: 24818590
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in addition to low dose aspirin and heparin
Study: 23182016
Drug: Red-light treatment
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red-light treatment (n = 10)
Study: 18316154
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 20% CO2-enriched air as unconditioned stimulus (US) during acquisition trials.
Study: 12055112
Drug: 1% escin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% escin gel
Study: 12055112
Drug: 2% escin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% escin gel
Study: 11064625
Drug: succinylcholine 1
Normalized name: Succinylcholine 124 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: succinylcholine 1 mg kg‐1
Study: 29452684
Drug: Pimavanserin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimavanserin (two 17 mg tablets daily)
Study: 24159051
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (n = 14)
Study: 12560443
Drug: Pegfilgrastim 100
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegfilgrastim 100 micro g/kg (single subcutaneous injection)
Study: 12560443
Drug: Filgrastim 5
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim 5 micro g/kg (daily subcutaneous injections)
Study: 31445316
Drug: Omega-3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplementation (2.5 g/d for 45 days)
Study: 29386889
Drug: UMEC 62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMEC 62.5 μg
Study: 27103795
Drug: TIO 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIO 18 μg
Study: 24568323
Drug: Medications for
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications for pain relief
Study: 16278614
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of micronized estradiol (n = 85)
Study: 16278614
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg of conjugated equine estrogens (n = 85)
Study: 10205099
Drug: Itraconazole 400
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole 400 mg a day for 1 week in every 4 weeks for 16 weeks (I4)
Study: 20308833
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg gestrinone
Study: 30366744
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine and haloperidol
Study: 30366744
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine with normal saline (Control)
Study: 19734176
Drug: Budesonide/formoterol (320/9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (320/9 microg, one inhalation twice daily)
Study: 17552386
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no sub-Tenon's space injection)
Study: 11510013
Drug: Rabbit antithymocyte
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabbit antithymocyte globulin (RATG) induction at a dose of 1.5 mg/kg IV
Study: 11510013
Drug: Methylprednisolone, 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone, 1,000 mg IV
Study: 9576460
Drug: Duodenal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duodenal infusion of heparinized autologous blood
Study: 3499211
Drug: Cytosine arabinoside/cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytosine arabinoside/cyclophosphamide pulses every eight weeks during continuation therapy
Study: 26056191
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg propafenone
Study: 23621906
Drug: Autologous blood
Normalized name: Banked autologous blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous blood injection
Study: 2863220
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg once a day)
Study: 12585167
Drug: Conventional plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional plus Salvia Injection (SI) intervention treated group (24 cases)
Study: 12585167
Drug: Conventional steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional steroid treated group (20 cases)
Study: 10368505
Drug: Tocolytic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocolytic agents used in abruptio placentae group (95 women, 73%)
Study: 10368505
Drug: Tocolytic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocolytic agents used in placenta previa group (78 patients, 72%)
Study: 10368505
Drug: Tocolytic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocolytic agents (combined patients: 171)
Study: 10368505
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not treated with tocolytic agents)
Study: 7025874
Drug: Pethidine 50
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 50 mg
Study: 2040318
Drug: Heparin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin alone (Control)
Study: 2040318
Drug: Decrease of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decrease of sigma-ST at 2 h post-treatment
Study: 31060586
Drug: DNA fragments
Normalized name: palmitoyl fragment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA fragments from Lactococcus lactis strain Plasma (LC‐Plasma) with varying CpG motif copy numbers and G + C contents.
Study: 22692704
Drug: AMG 386
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 386 at 10 mg/kg plus sorafenib 400 mg orally twice daily (arm A)
Study: 22692704
Drug: AMG 386
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 386 at 3 mg/kg plus sorafenib 400 mg orally twice daily (arm B)
Study: 22692704
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus sorafenib 400 mg orally twice daily (arm C)
Study: 18977820
Drug: L-dopa (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa (acute challenge)
Study: 8062610
Drug: Overnight urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overnight urinary albumin excretion rate (AER) determined by radioimmunoassay
Study: 11137810
Drug: 3mg sodium
Normalized name: glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3mg sodium nitroprusside in 10ml of 5% dextrose solution sprayed on the pedicle (Group I, n=42)
Study: 11137810
Drug: Half of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half of the sodium nitroprusside solution sprayed and half injected into the pedicle (Group II, n=44)
Study: 2902683
Drug: Betaxolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol (10 mg, intravenously)
Study: 25616355
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment (2.5 years of tamoxifen followed by 2.5 years of exemestane)
Study: 15149346
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose dialysis
Study: 15149346
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose dialysis
Study: 24419017
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation to supraspinatus, posterior deltoid & long head of biceps along with routine physiotherapy and occupational therapy for 5 weeks
Study: 24419017
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation to supraspinatus & posterior deltoid along with routine physiotherapy and occupational therapy for 5 weeks
Study: 22284923
Drug: Intramuscular vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vitamin A 10,000 IU 3 times weekly from day 2 for a minimum of 2 weeks or until establishment of oral feeding
Study: 18413705
Drug: CP-316,311 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-316,311 (400 mg twice daily)
Study: 23032478
Drug: Sertraline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (100 mg daily)
Study: 10911771
Drug: Efacal (Ca
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efacal (Ca 1.0 g, evening primrose oil 4.0 g, marine fish oil 440 mg)
Study: 10911771
Drug: Calcium alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium alone (Ca 1.0 g)
Study: 9192063
Drug: Budesonide (new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (new topical steroid)
Study: 19540640
Drug: Atorvastatin, 10
Normalized name: Amlodipine Besylate-Atorvastatin, 10 mg-80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin, 10 mg/d
Study: 8457023
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (100 micrograms sodium selenite daily for 14 weeks)
Study: 28421334
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring
Study: 21368663
Drug: Trimacinolone injection
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimacinolone injection (TA)
Study: 14662284
Drug: Vitamin-mineral supplement
Normalized name: Prenatal Vitamins Oral Tablet [PRENATAL VITAMIN-MINERAL SUPPLEMENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin-mineral supplement containing recommended daily allowance (RDA) dosages
Study: 31571853
Drug: Imidafenacin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidafenacin 0.2 mg
Study: 19651872
Drug: RTS,S/AS02D malaria
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS02D malaria vaccine candidate
Study: 12241657
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg rifapentine plus 900 mg isoniazid once a week
Study: 12241657
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg rifampicin plus 900 mg isoniazid twice a week
Study: 2142731
Drug: Naprosyn 500
Normalized name: Naprosyn 500mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naprosyn 500 mg b.i.d. for 30 days
Study: 25871017
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (40 g placebo powder daily for 2 months)
Study: 8996134
Drug: Clodronate 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 1,500 mg
Study: 8942149
Drug: ofloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ofloxacin 400 mg daily (BB)
Study: 8942149
Drug: ofloxacin 800
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ofloxacin 800 mg daily (CC)
Study: 8942149
Drug: clofazimine 50
Normalized name: clofazimine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: clofazimine 50 mg daily and 300 mg once in 4 weeks + dapsone 100 mg daily (AA)
Study: 20569733
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of autologous bone marrow mononuclear cells (BMMC)
Study: 11918829
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg acetaminophen (paracetamol) 6 times daily for 5 days
Study: 11918829
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ibuprofen 6 times daily for 5 days
Study: 10593430
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin twice daily (mean 20569 IU/day)
Study: 1755884
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml 0.5% bupivacaine with adrenaline
Study: 1755884
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml placebo
Study: 6612389
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg intravenous lidocaine
Study: 6612389
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg topical lidocaine
Study: 27406242
Drug: TIME intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIME intervention (multicomponent program including rigorous assessment, case conferences, treatment and evaluation of NPS)
Study: 24949564
Drug: Varenicline (VAR;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (VAR; 1 mg twice daily)
Study: 24733235
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose naltrexone (L-NTX; 25 mg once daily)